Jean-Charles Soria: Two provocative manuscripts suggest the therapeutic potential of JAK inhibition with immunotherapy in cancer
Jean-Charles Soria shared a post on LinkedIn:
“Two provocative manuscripts suggest the therapeutic potential of JAK inhibition in combination with immunotherapy in cancer.
In one paper, JAKi significantly reduced neutrophil-to-lymphocyte ratios and percentages of myeloid suppressor cells and rescued the function of exhausted T cells.
In the other paper, JAKi enhanced CD8 T cell plasticity by decreasing the inflammatory and IFN-I signals that drive terminal differentiation of CD8 T cells. In patients, this combination is suggestive of PD1 activity enhancement in both NSCLC and Hodgkin lymphoma.”
Source: Jean-Charles Soria/LinkedIn
Jean-Charles Soria serves as Amgen’s senior vice president of Oncology within Global Development. He is a medical oncologist and a professor of medicine at Paris-Saclay University. From 2017 to 2019, he was the senior vice president of Research and Development in Oncology at AstraZeneca.
Additionally, Soria has authored or co-authored over 670 articles in leading international journals and has been recognized as one of the world’s most influential research scientists.
